Corporate Compliance Program
Declaration of Compliance
PhRMA Code on Interactions with Healthcare Professionals
Dave Lemus promoted to Chief Executive Officer of Sigma-Tau Pharmaceuticals, Inc.
Sigma-Tau Pharmaceuticals launches Cystaran
for the treatment of corneal cystine crystal accumulation in patients with cystinosis
Sigma-Tau receives innovation award from the National Organization for Rare Disorders for its advancements in Rare Diseases
Sigma-Tau PharmaSource, Inc. and Aradigm Corporation Sign Manufacturing Agreement for the Clinical and Commercial Supply of Pulmaquin
Sigma-Tau Pharmaceuticals, Inc. Announces First Patient Dosed in Phase I/II Clinical Trial of STP206 for Prevention of Necrotizing Enterocolitis in Very Low Birth Weight Premature Infants.
| © 2014 Sigma-Tau Pharmaceuticals, Inc.